<DOC>
	<DOC>NCT01460836</DOC>
	<brief_summary>Matching-adjusted indirect comparison of tobramycin solution (TIS) versus aztreonam lysine (AZLI) using TIS patient level clinical trial data and AZLI aggregated clinical trial data from published literature.</brief_summary>
	<brief_title>Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>â‰¥ 6 years of age with a documented Cystic fibrosis (CF) diagnosis, moderateto severe lung disease, the ability to perform reproducible pulmonary function tests, Pseudomonas aeruginosa (PA) airway infection. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Cystic fibrosis</keyword>
</DOC>